Skip to main content
Premium Trial:

Request an Annual Quote

Microba, Synlab Ink Strategic Agreement to Launch Microbiome Test in Europe, Latin America

NEW YORK ─ Australian microbial genetics firm Microba said on Wednesday that it has inked an agreement with German medical diagnostic services provider Synlab to launch a gut microbiome test, MyBiome, in Europe and Latin America.

The test measures bacterial species in the gut microbiome and calculates their metabolic potential in relation to healthy reference ranges, Microba said.

The product launch will bring its whole-genome metagenomic sequencing and bioinformatics software to new markets, the Brisbane-based company said, and Synlab will make a new gastrointestinal testing service available to its network of doctors and clinics.

Microba's metagenomic analysis platform consists of a sampling technology and next-generation sequencing assay to analyze the genomes of the community of organisms living in the gut.

Microba CEO Blake Wills said in a statement that the product launch will expand the availability of the company’s gut microbiome analysis technology in Europe, a region with unmet demand for microbiome testing services.

Microba and Augsburg, Germany-based Synlab will launch the MyBiome gut microbiome test initially in Spain and Colombia.

In 2019, Microba announced that it had partnered with Macrogen to develop microbiome research services for international markets.

The Scan

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.